Efficacy of Local Antibiotic Injection Via a Catheter for Treating Acute Periprosthetic Infections After Knee DAIR Surgery (YES)

Efficacy of Local Antibiotic Injection Via a Catheter for Treating Acute Periprosthetic Infections After Knee DAIR Surgery: A Prospective, Randomized Controlled Trial Study

Prosthetic Joint Infection (PJI) is a severe complication following joint replacement surgery, imposing significant economic and health burdens on patients. For acute PJI, the DAIR (Debridement, Antibiotics, and Implant Retention) procedure is a necessary and effective treatment method, as it effectively clears the infection while preserving the prosthesis, thereby avoiding more complex surgical interventions. However, the practice of using drainage tubes postoperatively is controversial. Some studies suggest that drainage tubes may increase the risk of infection, while other literature indicates no statistically significant difference in infection risk associated with their use.In this context, Professor Li Cao's team at Xinjiang Medical University has improved the traditional DAIR procedure by incorporating long-term local antibiotic injections post-surgery, achieving positive results. Despite this, the specific method of antibiotic injection, particularly whether to use a drug infusion tube, remains under debate. The use of an infusion tube can reduce patient discomfort, shorten the local disinfection process, and theoretically decrease the time the incision is exposed to the external environment, potentially lowering the infection risk. However, the validity of these theoretical assumptions needs further confirmation through high-level scientific research. This study aims to evaluate whether there are differences in joint function recovery, changes in blood infection markers, and the incidence of postoperative complications between using and not using an infusion tube for local antibiotic injection after knee DAIR surgery. To assess the value of the infusion tube in local antibiotic injection post-knee DAIR surgery, a randomized controlled trial (RCT) will be conducted. Eligible patients will be randomly assigned to the infusion tube group (experimental group) or the non-infusion tube group (control group). The study will prospectively collect basic information, joint function scores, blood infection markers, and postoperative complication data from both groups, including patient age, gender, educational background, and postoperative blood test results. Ultimately, the RCT aims to demonstrate the therapeutic efficacy of the infusion tube method.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age ≥18 years old, gender is not limited;
  2. Meet the diagnostic criteria for DAIR surgery of artificial knee joint;
  3. Receiving knee DAIR surgery;
  4. Voluntary and signed informed consent.

Exclusion Criteria:

  1. Patients with chronic PJI infection undergoing total knee revision;
  2. Patients with severe knee joint infection who cannot undergo artificial joint replacement;
  3. Progressive renal insufficiency (stage 4 and above) or glomerular filtration rate less than 30ml/min;
  4. periprosthesis infection after multiple joint replacement;
  5. Active infection at the site of intravenous or joint injection;
  6. long-term use of anticoagulants or antiplatelet drugs due to other diseases;
  7. Have sepsis or positive blood culture within the last 30 days;
  8. Radiotherapy and chemotherapy are required due to neoplastic diseases;
  9. Receiving systemic glucocorticoid therapy (prednisone > 10mg/ day or equivalent hormone medication);
  10. severe immunodeficiency diseases (such as stage 3 HIV, sickle cell anemia, splenectomy, etc.);
  11. Have a history of drug abuse;
  12. Treatment of bone marrow or other transplants with immunosuppressive drugs;
  13. Pregnant, parturient and lactating women;
  14. Participating in other clinical trials;
  15. Researchers believe that other reasons are not appropriate for clinical trial participants.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Catheter group
Using catheter after knee DAIR surgery.
With or without using catheter after DAIR operation for drug infusion.
Active Comparator: None-catheter group
Without using catheter after knee DAIR surgery.
With or without using catheter after DAIR operation for drug infusion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Infection control rate
Time Frame: Two year after surgery
Infection control rate
Two year after surgery
Time between infection recurrence
Time Frame: Two year after surgery
Time between infection recurrence
Two year after surgery
Re-operation rate
Time Frame: Two year after surgery
Re-operation rate
Two year after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
X-ray
Time Frame: One day before surgery and two years after surgery
X-ray
One day before surgery and two years after surgery
American Knee Society Score (AKS score)
Time Frame: One day before surgery and two years after surgery

American Knee Society Score is used to evaluate the outcomes of knee replacement surgery. This scoring system consists of two main components: the knee score and the function score.

Knee Score: This primarily assesses the condition of the knee joint itself, including pain, stability, and range of motion. The higher of the score, the better of the functional result.

One day before surgery and two years after surgery
Redness, Edema, Ecchymosis, Discharge, and Approximation score (REEDA score)
Time Frame: One day before surgery, three month after surgery
The REEDA score is a clinical tool used to assess the healing of perineal wounds and other skin wounds, particularly after childbirth. REEDA stands for Redness, Edema, Ecchymosis, Discharge, and Approximation. Each of these five parameters is scored on a scale from 0 to 3, with higher scores indicating more severe symptoms. The total REEDA score can range from 0 to 15.
One day before surgery, three month after surgery
Visual Analog Scale score
Time Frame: One day before surgery and two years after surgery
The VAS score, or Visual Analog Scale, is a tool commonly used to measure a person's level of pain. The VAS is a simple, subjective measure that consists of a straight line, typically 10 centimeters long, anchored by two endpoints. One end of the line represents "no pain" and the other end represents "worst pain imaginable." For example, if the VAS line is 10 cm long and the patient's mark is at 7 cm from the "no pain" end, their pain score would be 7 out of 10.
One day before surgery and two years after surgery
White blood cell count
Time Frame: One day before surgery and one day after surgery
White blood cell count from blood
One day before surgery and one day after surgery
Erythrocyte sedimentation rate (ESR)
Time Frame: One day before surgery and one day after surgery

It measures the rate at which red blood cells settle to the bottom of a test tube within one hour.

Normal ranges:

Male: 0 to 15 millimeters per hour (mm/hr) Female: 0 to 20 millimeters per hour (mm/hr)

One day before surgery and one day after surgery
C-reactive protein (CRP)
Time Frame: One day before surgery and one day after surgery
C-reactive protein (CRP) is a protein produced by the liver that significantly increases in response to inflammation or infection. Normal range for CRP is less than 10 milligrams per liter (mg/L).
One day before surgery and one day after surgery
Synovial fluid white blood count
Time Frame: One day before surgery and one day after surgery
Synovial fluid white blood count
One day before surgery and one day after surgery
Polymorphonuclear neutrophil percentage in synovial fluid (SF-PMN)
Time Frame: One day before surgery and one day after surgery
Polymorphonuclear neutrophil percentage in synovial fluid refers to the proportion or percentage of polymorphonuclear neutrophils (PMN) present in the synovial fluid. This measurement is important in the assessment of joint health and inflammation, particularly in conditions such as arthritis and infections affecting the joints. Normal range: Less than 80%.
One day before surgery and one day after surgery
Alanine Aminotransferase (ALT)
Time Frame: One day before surgery and one day after surgery
An enzyme found in the liver that helps convert proteins into energy. Elevated levels indicate liver damage. Normal range: 10 to 40 units per liter (U/L)
One day before surgery and one day after surgery
Aspartate Aminotransferase (AST)
Time Frame: One day before surgery and one day after surgery
An enzyme found in the liver and other tissues. High levels can indicate liver damage but are less specific than ALT. Normal range: 10 to 40 units per liter (U/L)
One day before surgery and one day after surgery
Serum Creatinine
Time Frame: One day before surgery and one day after surgery
Measures the level of creatinine in the blood. Elevated levels can indicate impaired kidney function. Normal range: 62 to 115 micromoles per liter (µmol/L).
One day before surgery and one day after surgery
Blood Urea Nitrogen (BUN)
Time Frame: One day before surgery and one day after surgery
Measures the amount of nitrogen in the blood that comes from urea. Elevated BUN levels can indicate impaired kidney function. Normal range: 2.5 to 7.1 millimoles per liter (mmol/L).
One day before surgery and one day after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Li Cao, M.D., The first affliated hospital, Xinjiang medical university

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

August 1, 2024

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

June 12, 2024

First Submitted That Met QC Criteria

June 15, 2024

First Posted (Actual)

June 21, 2024

Study Record Updates

Last Update Posted (Actual)

June 21, 2024

Last Update Submitted That Met QC Criteria

June 15, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Rawdata can be asked after paper published.

IPD Sharing Time Frame

Rawdata can be asked after paper published.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Drug infusion into joint through catheter.

3
Subscribe